Gain useful insights into why investing in Africa is strategically important for the pharmaceutical industry, where the specific opportunities are and their nature and how companies can develop a sustainable business model to address the dynamics of the market in Africa today and in the future. Download our 24 page whitepaper.
PharmaFocus Reports, February 2012
South Africa offers distinct opportunities to launch new drugs and conduct clinical research related to pharmaceuticals. Omar Ehsan, Linda Reid and Symon Vokes discuss South Africa’s pharmaceutical market, offering perspective on key trends and dynamics.
Emerging Strategies: Faced with Change, Pharmaceutical Firms Shift Business Mix to Generics and Emerging Markets
Chemical & Engineering News, October 2011
Between now and 2015, about $138 billion in drug sales across eight major developed markets will be at risk to generic competition. Multinational pharmaceutical companies are looking to generic products and emerging markets, and much is riding on how well they balance their new and old businesses.
PharmaVoice, October 2011
With a diverse population, thriving research environment, strong infrastructure, and access into the rest of Africa, South Africa offers significant advantages for global pharmaceutical manufacturers.
Pharmaceutical Executive, August 2011
Our experts share their insights about anticipating risk, staying agile, understanding culture, and dropping the HQ comfort-zone mentality to achieve commercial excellence in the pharmerging markets.
Pharmaceutical Market Europe, May 2011
Turkey has always been a bridge between Europe and Asia with untapped promise in a variety of industries. We explore the unique opportunities this market offers and how pharmaceutical manufacturers can tap into its potential.
IMS White Paper, 2011
Rapid growth and rich potential vie with complex challenges in the APAC markets as government pressure on pricing intensifies. With an eye on revealing the real opportunities, our periodical considers the price/volume dilemma playing out in APAC, the implications of Taiwan’s health insurance reforms, and the growing importance of the pharmacy channel in Malaysia.
IMS White Paper, 2011
A consistent outperformer in the global arena, the oncology sector merits close consideration – particularly in the APAC markets of Australia, China and Japan. In this white paper, our Asian market experts consider the growing opportunities for standard therapies, the openings for new strategic players, and critical factors for gaining a meaningful foothold.
IMS White Paper, September 2010
China, the only first-tier pharmerging market country benefitting from numerous reforms and a growing healthcare infrastructure, is the focus of increasing interest and activity among pharma manufacturers. Companies that venture there must take into account a number of emerging issues and residual challenges, including the accessibility and affordability of medicines.
Pharmaceutical Executive, August 2010
IMS, Pfizer and Merck share their perspectives on the industry's expanding vision for emerging markets. Our consultants outline seven principles that will help drive success in both first- and second-tier emerging markets.
IMS White Paper, March 2010
Using our proprietary market assessment and forecasting capabilities, we identify three levels of pharmerging markets, and how growth opportunities can be maximized in 17 high-potential countries.
Join IMS’s Sarah Rickwood with Ernest Darkoh and John Sargent of BroadReach Healthcare.
IMS Consulting Group’s David Campbell brings to light the opportunities in emerging markets, the types of companies that have the best chance for success, and what must be done differently to ensure success.